A Randomized Controlled Trial of the N-methyl-D-aspartate (NMDA) Receptor Antagonist Ketamine in Comorbid Depression and Alcohol Dependence. (KetamineDep)

NCT01551329 Phase 1 COMPLETED

The purpose of this study is to evaluate the efficacy of ketamine in reducing depressive symptoms in subjects with a comorbid major depressive episode and alcohol dependence. The investigators hypothesize the following for the present study: A single dose of ketamine will induce a rapid, robust and sustained reduction in depressive symptoms in subjects with a comorbid major depressive episode and alcohol dependence relative to placebo as defined by change in Hamilton Depression Rating Scale total scores at 72 hours post infusion. A single dose of ketamine can be delivered safely, with minimal adverse events or complications, in subjects with a comorbid major depressive episode and alcohol dependence.

Details

Lead sponsor	Yale University
Phase	Phase 1
Status	COMPLETED
Enrolment	5
Start date	2012-03
Completion	2015-11

Conditions

• Depression
• Alcohol Dependence

Interventions

• Ketalar (ketamine)

Primary outcomes

• Depression — 29 Days
  Measured using the Hamilton Depression Rating Scale

Countries

United States